Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals' KIO-201 Heals Wounds in Phase 2 Trial of Patients with Persistent Corneal Epithelial Defects
In a second presentation, Kiora shared additional positive results for its KIO-100 platform in the treatment of autoimmune uveitis. Encinitas, California--(Newsfile Corp. - April 26, 2023) - Kiora Pharmaceuticals
Brianm Strem Francina Agosti Enriqueo Graue Hernandez California Newsfile Corp Kiora Pharmaceuticals Association For Research
Source: finanznachrichten.de